Expressed by over 68% of individuals of African descent and millions worldwide, the Fy(a-b-) phenotype is an evolutionary genetic variation—not an illness. We provide clarity for patients, diagnostic stewardship for clinicians, and translational data for biopharma.
Sub-Saharan African ancestry (Reich et al., Nat Genet 2009)
× 10⁹/L physiological range (Merz & Achebe, Blood 2019)
Often misclassified as 'abnormal' by standard reference intervals (Atallah 2019)
Avoidable via first-line ACKR1 test (Hsieh et al., 2007)
Understanding the molecular genetics, evolutionary history, and modern medical implications of the Fy(a-b-) phenotype.
Duffy null is caused by a single point mutation (rs2814778 / -46T>C) in the erythroid promoter region of the ACKR1 gene on Chromosome 1. This mutation specifically abolishes GATA-1 transcription factor binding, silencing Duffy protein expression on erythrocytes while leaving endothelial cell expression fully intact.
The Duffy glycoprotein historically served as the obligatory receptor for Plasmodium vivax merozoite invasion into red blood cells. The -46T>C mutation spread rapidly across Central and West Africa due to positive natural selection, conferring profound evolutionary protection against vivax malaria.
In modern clinical medicine, lack of clinical awareness leads to two major disparities: healthy individuals undergoing painful, unnecessary bone marrow biopsies for low white blood cell counts (DANC), and cancer patients facing inappropriate chemotherapy delays due to conventional commercial lab reference ranges.
Access tailored clinical workflows, patient guidance, or clinical trials and translational datasets.
Plain-language explanations of DANC, debunking infection myths, modern malaria facts, and our free printable Emergency Medical Wallet Card.
Evidence-based guidelines aligned with the American Society of Hematology (ASH), point-of-care ANC risk calculator, and chemo dose preservation protocols.
Live ClinicalTrials.gov study tracking, recent 2026 PubMed literature, erythrocyte ACKR1 chemokine sink biology, and clinical cohort inquiries.
They refer to the exact same biological finding. "Benign Ethnic Neutropenia" (BEN) was the historical term used for decades. Modern medical societies have shifted away from "ethnic" labels. The American Society of Hematology (ASH) officially adopted DANC (Duffy-Null Associated Neutrophil Count), while some academic literature also uses DAND (Duffy-Null Associated Neutrophil Decrease). DANC is now the preferred consensus nomenclature.
It is present in approximately 68% to 72% of African Americans and upwards of 95% to 100% of indigenous populations in West and Central Africa. It is also found in significant frequencies across parts of the Arabian Peninsula and Yemen. In individuals of European ancestry, it is virtually absent (less than 0.1%).
No. The Duffy-null phenotype does not cause anemia, fatigue, weakness, or impaired oxygen carrying capacity. Red blood cell survival, hemoglobin levels, and platelet counts are completely normal. If an individual experiences unexplained fatigue, standard workup for iron deficiency, thyroid dysfunction, or vitamin B12 deficiency should be performed.
Over 99% of Duffy-null individuals carry the erythroid-specific GATA promoter variant (-46T>C), which means endothelial cells still express Duffy protein. This confers natural immune tolerance, making anti-Fy3 antibody formation exceedingly rare; standard single-unit emergency transfusions are typically well tolerated. Prophylactic matching for rare Fy(a-b-) units is primarily reserved for chronically transfused patients (such as sickle cell disease) or rare complete gene deletion mutations.
DuffyNull.com is an independent digital health education platform and voluntary registry project dedicated to translating peer-reviewed hematology consensus (ASH, Blood, ASCO) into accessible diagnostic stewardship tools, clinical calculators, and patient advocacy.
We operate as an open health science initiative committed to eradicating unnecessary bone marrow biopsies and addressing structural inclusion barriers in clinical research. We do not provide individualized medical diagnoses or direct healthcare services. All clinical algorithms strictly reflect published consensus literature.